Personalized cancer vaccines from Moderna and Merck have added more than 50 billion dollars in combined market value for the two drugmakers. BTIG analyst Mark Massaro estimates that the genetic sequencing required for these vaccines could generate over 600 million dollars in annual revenue for diagnostics companies like Tempus AI, pending regulatory approval and expansion into lung, bladder, and kidney cancers. Minimal residual disease (MRD) testing, which monitors cancer recurrence after treatment, is seen as an even larger opportunity, with Natera controlling most of this market at a valuation near 45 billion dollars. BioNTech’s recent setback in a colorectal cancer vaccine trial nevertheless reminds investors that this sector remains unproven and that sentiment can shift quickly.
Source: Read the original article
